



Registered Charity Number: SC005895

| | Page |
|-----------------------------------|------|
| Trustees' Report | 3 |
| Independent Auditor's Report | 15 |
| Statement of Financial Activities | 20 |
| Balance Sheet | 21 |
| Statement of Cash Flows | 22 |
| Notes to the Financial Statements | 23 |

The images shown on the front cover are of the Queen Elizabeth University Hospital and the Royal Hospital for Children.

Trustees' Report - Trustees

| Name | Position |
|--|----------------------|
| Professor J Brown CBE (until 30 November 2023) | Chair |
| Dr L Thomson KC (from 1 December 2023) | Chair |
| Rev J Matthews OBE | Vice Chair |
| Mr I Ritchie | Vice Chair |
| Ms M Ashraf | Non-Executive Member |
| Cllr J Cameron | Non-Executive Member |
| Ms A Cameron-Burns | Non-Executive Member |
| Mr S Carr (until 31 August 2023) | Non-Executive Member |
| Mr A Cowan | Non-Executive Member |
| Cllr C Cunningham | Non-Executive Member |
| Ms J Forbes | Non-Executive Member |
| Ms D Foy | Non-Executive Member |
| Mr D Gould | Non-Executive Member |
| Mr G Haddock OBE (from 1 May 2023) | Non-Executive Member |
| Ms M Kerr | Non-Executive Member |
| Ms A M Monaghan | Non-Executive Member |
| Cllr M McCluskey (until 30 April 2024) | Non-Executive Member |
| Cllr C McDiarmid | Non-Executive Member |
| Cllr M McGinty | Non-Executive Member |
| Professor I McInnes CBE | Non-Executive Member |
| Dr R Metcalfe (from 1 September 2023) | Non-Executive Member |
| Ms K Miles | Non-Executive Member |
| Cllr K Pragnell | Non-Executive Member |
| Dr L Rousselet | Non-Executive Member |
| Dr P Ryan | Non-Executive Member |
| Mr F Shennan (until 31 May 2024) | Non-Executive Member |
| Ms R Sweeney | Non-Executive Member |
| Mr C Vincent | Non-Executive Member |
| Ms M Wailes | Non-Executive Member |

Executive Members

| Ms J Grant | Chief Executive |
|---------------------|---------------------------|
| Dr J Armstrong | Medical Director |
| Dr E Crighton | Director of Public Health |
| Professor A Wallace | Nurse Director |
| Mr C Neil | Director of Finance |

Advisers

Administration Office

Endowments Office NHS Greater Glasgow and Clyde 140 Fifty Pitches Road Cardonald Park Glasgow G51 4ED

Independent Auditor

BDO LLP 2 Atlantic Square 31 York Street Glasgow G2 8NJ

Bankers

RBS plc 8-10 Gordon Street Glasgow G1 3PL

Investment Managers

Newton Investment Management Ltd The Bank of New York Mellon Centre 160 Queen Victoria Street London EC4V 4LA

Lawyers

Scottish Central Legal Office Anderson House Breadalbane Street Bonnington Road Edinburgh EH6 5JR

<u>Trustees' Report for the year ended 31 March 2024</u>

The Trustees present their annual report and the audited financial statements for the year ended 31 March 2024.

The information with respect to Trustees and advisers set out from page 3 forms part of this report. The financial statements comply with United Kingdom Accounting Standards, including Financial Reporting Standard 102 (FRS102), the Charities Statement of Recommended Practice (SORP) 2019, the Charities and Trustee Investment (Scotland) Act 2005, and the Charities Accounts (Scotland) Regulations 2006.

Structure, Governance and Management

NHS Greater Glasgow and Clyde's powers to hold funds on trust are set out in Sections 82 to 84 of the NHS Scotland Act 1978. The Charity is registered as a charity with the Office of the Scottish Charity Regulator under the number SC005895.

The Charity's objective is the advancement of health, through:

- a) improvement in the physical and mental health of the board's population;
- b) the prevention, diagnosis and treatment of illness;
- c) the provision of services and facilities in connection to the above; and
- d) research into any matters relating to the causation, prevention, diagnosis or treatment of illness, or into such other matters relating to the health service as the Trustees see fit.

The Trustees shall observe the principal of not granting charitable funds as a substitute for a core provision, or to cover a responsibility of the NHS Greater Glasgow and Clyde (NHSGGC) Board which is a requirement of health and safety, employment law or a ministerial policy direction. This is in order to reduce the risk of conflict of interest between the role of the NHSGGC Board and the Charity Trustees.

Trustee Appointment

The appointment as Trustee is legally distinct from the appointment as board members and individual board members, in their capacity as Charity Trustees, are required to meet the requirements of the Charities and Trustee Investment (Scotland) Act 2005. No other individuals are permitted to be appointed to act as Trustees.

The Trustees who served in the reporting period and up to the date of approval of these accounts are listed on page 3. The Trustees of the Charity are also members of the Board of NHSGGC. Non-executive members of the Board are appointed by Scottish Ministers and are selected on the basis of their position or the particular expertise which enables them to contribute to the decision-making process at a strategic level. The Trustees have agreed an Endowments Charter to govern the administration of the charity. Operational control of the management of the charity is delegated by the Trustees to the Healthcare Charity Committee (HCC) formerly Endowments Management currently chaired by Mr C Vincent. It was agreed by the Board of Trustees in April 2023 to change the known-as name of the charity to

Greater Glasgow and Clyde Healthcare Charity. A new logo was also approved.

The committee met 4 times during the year (9 May, 8 August, 14 November, and 12 February) and was chaired by Mr C Vincent.

The arrangements for the induction and on-going training of Trustees are reviewed on a regular basis. Trustees receive a comprehensive induction to the Charity when they join the Board, including an induction pack which includes the Charity's Charter, Trustee Role Description and Code of Conduct, and Conflict of Interest Policy. Members of the HCC are also invited to seminars and other development opportunities throughout the year on governance, investment, and charitable funding.

Financial Management

The Board's Standing Financial Instructions contain details of the scheme of delegation for Endowments and this includes budgetary control arrangements and provision for the delegation of responsibility to designated senior officials/trustees of the Board.

The remit of the HCC includes approval of annual budgetary proposals, monitoring of expenditure against budget and approval of proposals for individual items of expenditure in line with delegated authority. The HCC also considers grant requests mainly for expenditure from the general fund and has responsibility for the appointment of investment managers and advisers and receipt from them of periodic reports on performance.

It is also relevant to note that a significant body of restricted funds are of a custodian nature established at the request of designated fundholders and controlled by them on an operational basis, but subject to the general oversight of the Trustees.

Powers of Investment

NHS Greater Glasgow and Clyde's powers of investment in its capacity as corporate Trustee of the Greater Glasgow Health Board Endowment Funds are principally derived from the Charity's Charter and the Charities and Trustee Investment (Scotland) Act 2005: Trustees are entitled to make any kind of investment of the endowment including a wider power to acquire stocks and shares. Trustees' duties before making an investment are to consider the need for diversification of investments, consider the suitability of the proposed investments, and to consider obtaining appropriate advice. Trustees also have powers to appoint nominees (i.e. an investment manager) for the purpose of investment. Newton Investment Management ('Newton') have fulfilled this role for the Charity since their appointment in 2017.

Principal Risks and their Management

The risk management strategy for NHSGGC applies equally to the Endowment Funds. This was approved at the December 2022 NHSGGC Board meeting and is next due for review in December 2025. This is supported by a separate risk appetite statement specific to the Charity which was approved by the EMC in March 2023 and covers five key risk types: operating, legal, financial/commercial, reputational, and workforce.

Risk scoring is done on the basis of Likelihood x Impact = Risk Score.

- **Initial Score**: The score is assessed when the risk is first identified.
- **Current Score**: The risk score taking into account any controls that are currently in place to manage the risk.

The Board uses a 5 x 5 risk assessment scoring method as follows:

| | Extreme | Medium | High | High | V High | V High |
|--------|------------|-----------|---------------|---------------|-------------|---------------------|
| | 5 | 5 | 10 | 15 | 20 | 25 |
| | Major | Medium | Medium | High | High | V High |
| | 4 | 4 | 8 | 12 | 16 | 20 |
| | Moderate | Low | Medium | Medium | High | High |
| | 3 | 3 | 6 | 9 | 12 | 15 |
| _ | Minor | Low | Medium | Medium | Medium | High |
| | 2 | 2 | 4 | 6 | 8 | 10 |
| Impact | Negligible | Low | Low | Low | Medium | Medium |
| | 1 | 1 | 2 | 3 | 4 | 5 |
| , | | Rare 1 | Unlikely 2 | Possible 3 | Likely 4 | Almost Certain 5 |

Likelihood

Source: NHSGGC Risk Management Strategy

A risk register is maintained for the Charity which is reviewed annually by the HCC, with the most recent review taking place at its February 2024 meeting. The risk register currently details six risks which are summarised below.

| Risk Description | Risk Type | Initial Score | Current Score |
|---|---------------------------|---------------|------------------|
| Reduction in donation income | Financial / Commercial | 6 Medium | 4 Medium |
| Decrease in the valuation of the investment portfolio | Financial / Commercial | 16 High | 9 Medium |
| Ineffective decision making due to insufficient or incomplete reporting to the GCC Healthcare Charity Committee | Financial / Commercial | 16 High | 4 Medium |
| Risk of fraud or misuse of funds | Financial / Commercial | 16 High | 8 Medium |
| Gap in service provision to support the Endowment Fund / Trustees / Committee | Workforce | 12 High | 6 Medium |
| Non-compliance with | Operating | 16 High | 8 Medium |

| regulatory or operational | | |
|---------------------------|--|--|
| requirements | | |

Source: Greater Glasgow and Clyde Healthcare Charity Risk Register

Mitigating actions and controls have been discussed with the health board's Chief Risk Officer and agreed by the HCC, reflecting the reduction from the initial to the current scores above. Looking forward into 2024-25 and beyond, the principal area of uncertainty for the Charity is the volatility of investment values as global markets continue to contend with wider economic headwinds.

Performance review and plans for future periods

The Charity provides millions of pounds of charitable funding to projects that benefit staff and patients every year in line with the charitable objectives outlined earlier in this report. The Charity's budget is aligned to four overarching themes under which funding is provided, being: Healthy Spaces, Research and Education, Our People, and our Patients. Each overarching theme covers a number of sub-themes against which the Charity awards funding, as summarised below.



- Green/Outdoor Spaces
- Environmental Sustainability
- Patient and Family Infrastructure
- Staff Infrastructure
- Research
- Education and Training
- Innovation
- Peer Support and Review
- Leadership Development
- Endowments Finance Team
- Counselling and Psychology
- Patient and Families Welfare
- Community Services
- Palliative Care
- Population Health and Wellbeing

Source: Greater Glasgow and Clyde Healthcare Charity Committee

To accelerate spend from the funds, the HCC decided in April 2023 to proceed with the awarding of block grants, i.e. lump sum grants awarded under specific themes,

aligned to the overall strategic themes of the charity. Block grants awarded during 2023-24 included £100,000 recurring funding for investment in research facilities, £200,000 recurring funding to support wellbeing initiatives for staff, and £100,000 recurring funding to support environmental sustainability projects across the NHSGGC estate. Specific allocations from these block grants are delegated to governance sub-groups to ensure the funding is managed by individuals with the requisite knowledge of the specific projects being funded. Annual outcomes reports must be completed by award recipients to demonstrate how the funding has been applied to meet the project's objectives.

Each block grant covers a specific theme which is aligned to the Charity's strategic themes as shown below. We anticipate expenditure from these grants to accelerate moving into 2024-25 and beyond, as approved projects are established and begin their work.

In addition to this, larger project grants which were approved in 2023-24 by the Trustees, but not necessarily expended during the course of the year, included:

| <u>Project</u> | <u>Description</u> | <u>£</u> |
|---|--|-----------|
| Improving Psychosocial Care for Children and Young People with Epilepsy | Project to improve early access to mental health services for children and young people with epilepsy, with the aim of reducing the development of mental health difficulties in this patient group. | 175,561 |
| Retail Catering | Funding to support retail catering outlets across the NHSGGC estate as they emerge from the impacts of the Covid-19 pandemic and return to business as usual. | 1,047,500 |
| Home Start Glasgow South | Continuation of ongoing projects to provide antenatal and perinatal activities for new and prospective parents. | 98,829 |
| Veterans Support Service | Establishment of a new service, in partnership with the Defence Medical Welfare Service (DMWS) to provide welfare support to veterans on a medical pathway. | 247,850 |
| Medical Mentoring Scheme | A career mentoring scheme across a two year period for medical professionals across all grades within NHSGGC. | 71,000 |
| Enhanced Gynaecological Training | A recurring fund for gynaecology nurse training posts to support training of staff and deliver key services flexibility within the workforce. | 239,900 |

Other expenditure from restricted funds is, in accordance with the wishes of the relevant benefactors/sponsors, subject to the overall governance arrangements of the charity.

Another key area of focus for the Committee moving forward is the review of dormant restricted funds. The Committee aim to reorganise these funds, in line with statutory requirements as set out by the charities regulator, to allow the money to be spent advancing the Funds' charitable objectives and providing public benefit.

Financial Review

The statement of financial activities for the year is set out on page 20 of the financial statements. A summary of the financial results and the work of the charity are set out below.

The charity's overall income for the year was £10.4M which represents an increase of £1.5M compared with the prior year. Income is categorised into four main headings which are: donations and legacies, being donations from individuals, charitable foundations, corporate bodies and legacies; income from charitable activities which includes sponsorship of research activity, and fee income from courses/other services provided by clinical staff; and investment income. There is a final category of other income covering all income not listed above.

The charity does not engage directly in fundraising activities. Expenditure incurred on raising funds relates exclusively to fees paid to the Fund's investment manager.

Income from donations and legacies was approximately £0.4M higher than that in the prior year. This is mainly due to having a higher amount of donations from charitable and corporate organisations in the current year compared to 2022-23. Legacy income was approximately half of that received in the prior year, however, it should be noted that the level of individual legacies fluctuates year on year.

Income from charitable activities was £0.6M greater than the prior year due to income from clinical trials/research. Income generated from investments was approximately £0.5M greater than the prior year and this was across categories of both dividend income and fixed interest securities.

Total expenditure from unrestricted funds amounted to £4M, compared with £2M in the prior year. The spend from General Fund included support for a range of patient and staff amenity expenditure, voluntary services, as well as specific budget allocations from the General Funds as noted above. Expenditure from restricted funds was £0.7M greater than for the previous year, with research costs (£5.5M) and staff travel and training (£1M) being the largest areas of spend from restricted funds.

The HCC approved a total budget of £8.5M across the Fund's budget themes for the 2023-24 financial year, with £3.8M of expenditure incurred in-year. It is typical for there to be a delay between the funding approval and the expenditure being incurred while the projects for which funding has been provided get established and become operational.

Reserves

The Trustees have established a policy whereby a proportion of unrestricted funds has been set aside to cover management costs and routine patient/staff amenity expenditure. It is considered that the level of investments carried is required to generate sufficient income to maintain charitable activities. It is envisaged that the remaining "free reserves", including investments will be utilised over a period of years to fund a phased programme of non-recurring expenditure. Free reserves amounted to £15.2m (2022-23: £17.8m) and these consist of unrestricted funds.


Investment Policy and Performance

The Trustees' investment objective is to maximise the overall rate of return. Investments currently comprise three separate portfolios, denoted as the A, B and C portfolios.

- The objective of the "A" portfolio is to achieve a return equivalent to the Retail Price Index plus 3%-4% per annum over the long term through a broadly diversified portfolio. This includes a mixture of equities, gilts/bonds, and a minimum level of cash investment.
- The "B" portfolio is a lower risk holding intended to cover those funds where protection from capital fluctuation is necessary and is invested in Newton's Global Dynamic Bond Fund.
- Portfolio "C" is a cash holding with level of investment to cover cash requirements throughout the year.

The Trustees have agreed to a moderate tolerance of risk, accepting that at times this will mean accepting short or medium-term declines in capital values. Newton Investment Management was appointed as fund manager effective from 1 April 2017. This contract can be terminated at any time by either party subject to minimum 90 days' notice period. The performance of the investment portfolio is monitored in the quarterly reports provided by the investment managers with the target being to outperform agreed composite benchmarks over rolling 3-year periods.

The return on investment (shown net of fees) achieved by the fund manager over the most recent three calendar years is shown below.



The funds have generally performed well against benchmark, while also recognising 2022 which saw significant investment losses largely as a result of the conflict in Ukraine and ongoing inflationary concerns. Performance again fell below benchmark during 2023 as a result of interest rates persisting at higher levels for longer than anticipated, and a slower than expected COVID-19 recovery in key global economies such as China.

The consolidated asset allocation as at 31 March 2024 was as follows:

| | % |
|-------------------------|-------|
| UK Equities | 56 |
| UK Fixed Income | 9 |
| Unit Trusts | 25 |
| Commodities/Derivatives | 2 |
| Cash | 8 |
| Total | 100.0 |

The year-end market value of the investment portfolio administered by Newton was £103.2M compared with £99.1M in the prior year. The increase in carrying value was due to net investment gains (realised and unrealised) of £4.0M. Good investment performance, particularly across UK equities in the second half of the financial year, contributed positively to increases in market value within the portfolio.

Investment management costs of £492k were incurred in 2023-24 (2022-23: £472k). The investment management fee is calculated in accordance with the fee scale agreed at time of last tender and effective from 1 April 2017.

Ethical and Responsible Investment

The Fund is managed according to the Greater Glasgow and Clyde ethical policy, implemented using Ethical Investment Research and Information Services (EIRIS). The fund manager, in particular in the equity portfolio, is encouraged to take an active approach to engagement in Environmental, Social and Governance (ESG)

issues when considering both existing and prospective investments.

The Trustees maintain the following investment restrictions, which would be in direct conflict with the Charity's objectives:

- No direct investments in companies involved in tobacco production, distillers of alcoholic beverages, armaments or fossil fuels. Screened at 10% of turnover.
- No direct investment in issuers that breach the UN Global Compact Principals of corporate sustainability.

Disclosure of Information to the Auditor

So far as the Trustees are aware at the time the report is approved:

- there is no relevant audit information of which the charity's auditor is unaware, and
- the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees' Report is approved and signed on behalf of the Board

Colin Neil

DocuSigned by:

779B25B1512F464...

Colin Neil 25 June 2024

Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' report and the annual accounts in accordance with applicable law and regulations.

Charity law requires the Trustees to prepare financial statements for each financial year in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under charity law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the recommendations of the Statement of Recommended Practice have been followed, subject to any material departures disclosed and explained in the financial statements:
- state whether the financial statements comply with applicable accounting standards and the requirements of the National Health Service (Scotland) Act 1978, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue its activities.

The Trustees are required to act in accordance with the National Health Service (Scotland) Act 1978, within the framework of trust law. They are responsible for keeping adequate accounting records, sufficient to disclose at any time, with reasonable accuracy, the financial position of the charity at that time, and to enable the Trustees to ensure that, where any statements of accounts are prepared by them under section 44 of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), those statements of accounts comply with the requirements of regulations under that provision. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Charity and to prevent and detect fraud and other irregularities.

Financial statements are published on the charity's website in accordance with legislation in the United Kingdom governing the preparation and dissemination of financial statements, which may vary from legislation in other jurisdictions. The maintenance and integrity of the charity's website is the responsibility of the Trustees. The Trustees' responsibility also extends to the ongoing integrity of the financial statements contained therein.

INDEPENDENT AUDITOR'S REPORT TO TRUSTEES OF GREATER GLASGOW HEALTH BOARD ENDOWMENT FUNDS

Opinion on the financial statements

In our opinion, the financial statements:

- give a true and fair view of the state of the Charity's affairs as at 31 March 2024 and of its incoming resources and application of resources for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006, as amended.

We have audited the financial statements of the Greater Glasgow Health Board Endowment Funds ("the Charity") for the year ended 31 March 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remain independent of the Charity in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions related to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised

for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion;

- the information given in the Trustees' Report for the financial year for which the financial statements are prepared is inconsistent in any material respect with the financial statements;
- proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit

Responsibilities of Trustees

As explained more fully in the Trustees' Responsibilities Statement, the Trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Charity or to cease operations, or have no

realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Non-compliance with laws and regulations Based on:

- Our understanding of the Charity and the sector in which it operates;
- Discussion with management and those charged with governance; and
- Obtaining and understanding of the Charity's policies and procedures regarding compliance with laws and regulations;

we considered the significant laws and regulations to be compliance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities SORP (FRS 102) and the requirements of the Charities Accounts (Scotland) Regulations 2006.

The Charity is also subject to laws and regulations where the consequence of noncompliance could have a material effect on the amount or disclosures in the financial

statements, for example through the imposition of fines or litigations.

Our procedures in respect of the above included:

- Review of minutes of meeting of those charged with governance for any instances of non-compliance with laws and regulations;
- Review of correspondence with regulatory authorities for any instances of noncompliance with laws and regulations;
- Review of financial statement disclosures and agreeing to supporting documentation;
- Review of legal expenditure accounts to understand the nature of expenditure incurred.

Fraud

We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included:

- Enquiry with management and those charged with governance regarding any known or suspected instances of fraud;
- Obtaining an understanding of the Charity's policies and procedures relating to:
 - o Detecting and responding to the risks of fraud; and
 - o Internal controls established to mitigate risks related to fraud.
- Review of minutes of meeting of those charged with governance for any known or suspected instances of fraud;
- Discussion amongst the engagement team as to how and where fraud might occur in the financial statements:
- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;

Based on our risk assessment, we considered the areas most susceptible to fraud to be management override of controls and completeness of legacy income.

Our procedures in respect of the above included:

- Testing a sample of journal entries throughout the year, which met a defined risk criteria as well as a further random sample, by agreeing to supporting documentation;
- Assessing significant estimates made by management for bias, including accrual of investment income agreeing to third party documentation: and
- Review of legacy income received post year end:

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from

error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council's ("FRC's") website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the Charity's trustees, as a body, in accordance with the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the Charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity and the Charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

— DocuSigned by:

Mastin Gill

— B6616A8E69ED4ED

Martin Gill BDO LLP, statutory auditor 2 Atlantic Square 31 York Street Glasgow G2 8NJ

25 June 2024

BDO LLP is eligible for appointment as auditor of the charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

| Income and Endowments From: | Notes | Unrestricted Funds £'000 | Restricted Funds £'000 | Endowment Funds £'000 | Total 2024 £'000 | Unrestricted Funds £'000 | Restricted Funds £'000 | Endowment Funds £'000 | 2023 |
|---|-------|--------------------------------|------------------------------|-----------------------------|------------------------|--------------------------------|------------------------------|-----------------------------|---------|
| Donations and Legacies | 2 | 59 | 997 | _ | 1,056 | 27 | 656 | _ | 683 |
| Charitable Activities | _ | 1 | 6,243 | _ | 6,244 | - | 5,654 | _ | 5,654 |
| Investments | 3 | 588 | 2,347 | 198 | 3,133 | 780 | 1,591 | 220 | 2,591 |
| Other | - | 1 | 2 | - | 3 | - | 9 | - | 9 |
| Total | | 649 | 9,589 | 198 | 10,436 | 807 | 7,910 | 220 | 8,937 |
| Expenditure On: | | | | | | | | | |
| Raising Funds | 4 | 101 | 357 | 34 | 492 | 142 | 290 | 40 | 472 |
| Charitable activities | 4 | 3,926 | 8,353 | 24 | 12,303 | 1,802 | 7,688 | 20 | 9,510 |
| Total | | 4,027 | 8,710 | 58 | 12,795 | 1,944 | 7,978 | 60 | 9,982 |
| Net (Expenditure)/Income Before Investment Gains/(Losses) | 5 | (3,378) | 879 | 140 | (2,359) | (1,137) | (68) | 160 | (1,045) |
| Net Gains/(Losses) on Investments | | 1,027 | 2,621 | 361 | 4,009 | (689) | (1,405) | (195) | (2,289) |
| Net Income/(Expenditure) | | (2,351) | 3,500 | 501 | 1,650 | (1,826) | (1,473) | (35) | (3,334) |
| Transfers between Funds | | (294) | 294 | - | - | (674) | 674 | - | - |
| Net Movement in Funds | | (2,645) | 3,794 | 501 | 1,650 | (2,500) | (799) | (35) | (3,334) |
| Total Funds Brought Forward as at 1 April | | 17,807 | 81,218 | 5,438 | 104,463 | 20,307 | 82,017 | 5,473 | 107,797 |
| Total Funds Carried Forward at 31 March | 1 | 15,162 | 85,012 | 5,939 | 106,113 | 17,807 | 81,218 | 5,438 | 104,463 |

All Income and expenditure relates to continuing activities.

Greater Glasgow Health Board Endowment Funds Accounts For the Year Ended 31 March 2024 Balance Sheet

| | Notes | 2024 £'000 | 2023 £'000 |
|--|-------|--------------------|------------------------|
| FIXED ASSETS Investments | 7 | 103,222 | 99,133 |
| Total Fixed Assets | | 103,222 | 99,133 |
| CURRENT ASSETS Debtors Cash at bank and in hand TOTAL CURRENT ASSETS | 8 | 2,658 3,369 | 1,734 6,850 ———— |
| CURRENT LIABILITIES | - | <u>`</u> | |
| Creditors due within one year | 9 | (3,136) | (3,254) |
| Net current assets | | 2,891 | 5,330 |
| Total assets less current liabilities | • | 106,113 | 104,463 |
| THE FUNDS OF THE CHARITY: | | | |
| Endowment Funds | 12 | 5,939 | 5,438 |
| Restricted Funds | 12 | 85,012 | 81,218 |
| Unrestricted Funds | 12 | 15,162 | 17,807 |
| TOTAL CHARITY FUNDS | | 106,113 | 104,463 |

Adopted by the Trustees on 25 June 2024

DocuSigned by:

-779B25B1512F464...

Colin Neil Trustee

Greater Glasgow Health Board Endowment Funds Accounts For the Year Ended 31 March 2024 Statement of Cash Flows

| CASH FLOWS FROM OPERATING ACTITIVITES: | Notes | 2024 £'000 | 2023 £'000 |
|--|-------|---------------|---------------|
| Net cash used in operating activities | 13 | (6,530) | (5,406) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | | |
| Interest and dividends received | | 3,281 | 2,539 |
| Payments to acquire investments | | (8,955) | (11,958) |
| Receipts from sale of investments | | 7,363 | 12,231 |
| Net cash provided by investing activities | | 1,689 | 2,812 |
| Decrease in cash in year | 14 | (4,841) | (2,594) |
| Cash and cash equivalents at the beginning of the year | | 16,767 | 19,361 |
| Cash and cash equivalents at the end of the year | _ | 11,926 | 16,767 |
| Cash and cash equivalents is represented by: | | | |
| Cash at bank | | 3,369 | 6,850 |
| Cash held for re-investment | | 8,557 | 9,917 |
| | | 11,926 | 16,767 |

Notes to the financial statements for the year ended 31 March 2024

1 Significant accounting policies

1.1 Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charity SORP (FRS 102)), and The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

The NHSGGC Healthcare Charity is an unincorporated charity registered in Scotland with the Office of the Scotlish Charity Regulator (OSCR) under the number SC005895. Its powers to hold funds on trust are set out in sections 82 to 85 of the NHS Scotland Act 1978. Details of its administrative office (registered office) are included on page 4. These financial statements are presented in pounds sterling (GBP) as that is the currency in which the Charity's transactions are denominated.

The Charity meets the definition of a public benefit entity (PBE), as defined in FRS 102.

The financial statements are prepared in accordance with the historical cost convention, modified by the revaluation of investment assets.

The preparation of financial statements requires the use of certain critical accounting estimates and requires Trustees to exercise their judgement in the process of applying the accounting policies. The only material estimate applied in these financial statements relates to the carrying value of investments as disclosed in Note 1.10.

1.2 Going Concern

The accounts are prepared on the going concern basis, which provides that the entity will continue in operational existence for the foreseeable future. The Trustees have considered a period of at least 12 months from the signing of the financial statements and have not identified any material uncertainties that may cast significant doubt on the Charity's ability to meet its obligations as they fall due in the foreseeable future.

1.3 Income

Donations and legacies are credited to the statement of financial activities on a receivable basis. Legacies are accounted for on receipt of correspondence from the personal representative indicating that payment of the legacy will be made.

Fees receivable and charges for services, for example from the completion of medical tests or delivery of training courses, are accounted for in the period in which the revenue is receivable. Incoming resources are included gross of any tax recoverable.

Grants receivable and research sponsorship income are credited to the statement of financial activities in the year in which they are receivable.

Income from investments is included in the year in which it is due.

1.4 Expenditure and recognition of liabilities

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. The costs of raising funds are those incurred in making payments to the Fund's investment manager and do not include the costs of disseminating information in support of charitable activities.

Charitable expenditure is classified to reflect the main areas of activity of the charity with a more detailed analysis given in the notes to the accounts. All expenditure is allocated directly to the appropriate expenditure heading.

Management and administration costs, excluding governance costs, which are separately disclosed, have been apportioned to the various activity categories pro rata to the level of expenditure. Governance costs include those costs associated with meeting the constitutional and statutory requirements of the Charity. This includes costs related to the statutory audit.

Liabilities arise from legal or constructive obligations that commit the charity to expenditure. A liability and related expenditure are recognised when all of the following criteria are met:

- Obligation a present legal or constructive obligation exists at the reporting date as a result of a past event.
- Probable it is more likely than not that a transfer of economic benefits, often cash, will be required in settlement.
- Measurement the amount of the obligation can be measured or estimated reliably.

1.5 Taxation and VAT

The Charity has charitable status and is exempt from income tax under Section 505 of the Income and Corporation Taxes Act 1988 and capital gains tax under Section 256 of the Taxation of Chargeable Gains Act 1992 and the Charity is entitled to describe itself as a Scottish charity. Any irrecoverable VAT is charged to the statement of financial activities or capitalised as part of the cost of the related asset, where appropriate. The Charity is not separately registered for VAT. As permitted by HM Revenue & Customs (HMRC) under the NHS Contracted Out Services Regulations, VAT on relevant invoices paid from Endowment Funds is reclaimed using NHSGGC's own VAT registration reference. Amounts reclaimed are credited to the endowment funds which bore the costs initially.

1.5 Cash and cash equivalents

Cash and cash equivalents includes cash in hand, balances held in commercial banks and any other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts.

1.6 Fund accounting

Unrestricted funds are funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Endowment funds represent those assets which must be held permanently by the charity. Solely the income generated from those assets may be spent in accordance with the donors' wishes.

Investment income and gains are allocated across the appropriate funds.

1.7 Investments

Investments are included at closing bid-market value at the balance sheet date. Any realised and unrealised gains and losses on revaluation or disposals are combined in the statement of financial activities.

1.8 Financial Instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

1.9 Staff costs

The Charity is a grant making charity and has no employees (Charity staff are employees of NHS Greater Glasgow and Clyde), therefore there is no pension liability recognised. The staff costs disclosed in these financial statements reflect recharged salaries from the health board incurred in the day-to-day operation of the charity.

1.10 Significant judgements and estimates

The Charity makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The Charity makes judgements in applying accounting policies. The only material estimate relates to the determination of carrying value of investments at fair value through the Statement of Financial Activities.

1.11 Post Balance Sheet Events

Where events take place after the financial year-end but before the signing of the annual accounts, and provide information about conditions existing as at 31 March, the figures in the financial statements and notes are adjusted in all material aspects to reflect the impact of this information. No such events have been identified for the 2023-24 financial statements.

| 2. DONATIONS AND LEGACIES | | | | | | |
|--|------------------|--------------|--------------|------------------|-----------------------|--------------|
| | | | | | 2024 | 2023 |
| | | | | | £'000 | £'000 |
| Donations from Individuals | | | | | 258 | 213 |
| Donations from Charitable Foundations | | | | | 495 | 59 |
| Corporate Donations | | | | | 126 | 61 |
| Legacies | | | | | 177 | 350 |
| TOTAL | | | | _ | | 683 |
| | | | | _ | | |
| 3. INVESTMENT INCOME | | | | | | |
| | | | | | 2024 | 2023 |
| | | | | | £'000 | £'000 |
| Dividends | | | | | 1,168 | 1,446 |
| Interest on fixed interest securities | | | | | 1,572 | 1,020 |
| Bank and building society interest | | | | | 393 | 125 |
| TOTAL | | | | _ | 3,133 | 2,591 |
| 4. EXPENDITURE | | | | | | |
| | Paising | Charitable | | Daising | Ob a vita bla | |
| | Raising Funds | activities | 2024 | Raising Funds | Charitable activities | 2023 |
| | £'000 | £'000 | | £'000 | £'000 | £'000 |
| Investment Management Costs | | 2 000 | £'000 492 | £ 000 472 | £ 000 | £ 000 472 |
| Investment Management Costs Research Salaries and Supplies | 492 | - 6.470 | | 412 | 5,102 | 5,102 |
| Donations | - | 6,479 554 | 6,479 554 | <u>-</u> | (14) | • |
| Furniture and Equipment | - | 300 | 300 | _ | 952 | (14) 952 |
| Projects/Building Alterations | - | 478 | 478 | - | 441 | 441 |
| IT Equipment | - | 295 | 295 | - | 92 | 92 |
| Staff Travel/Conference Expenses | - | 1,218 | 1,218 | - | 830 | 830 |
| Staff Bursaries | - | 76 | 76 | <u>-</u> | 49 | 49 |
| Staff Amenities | - | 205 | 205 | _ | 131 | 131 |
| Staff Salaries/Lecture Fees | - | 30 | 30 | _ | 22 | 22 |
| Publications/Staff Libraries | - | 227 | 227 | _ | 142 | 142 |
| Professional Fees | - | 177 | 177 | _ | 731 | 731 |
| Patients' Amenities | _ | 824 | 824 | _ | 335 | 335 |
| Christmas Gifts | _ | 52 | 52 | _ | 55 | 55 |
| Governance Costs | _ | 23 | 23 | _ | 19 | 19 |
| General Management & Administrative Expenses | _ | 1,227 | 1,227 | _ | 324 | 324 |
| Other Expenditure | - | 138 | 138 | - | 299 | 299 |
| Total Expenditure | 492 | 12,303 | 12,795 | 472 | 9,510 | 9,982 |
| 5. NET INCOME/(EXPENDITURE) | | | | | | |
| | | | | | 2024 | 2023 |
| | | | | | £'000 | £'000 |
| Net income is stated after charging : | | | | | | |

No indemnity insurance for Trustee's liability has been purchased by the charity.

Auditors' remuneration for Audit Services

21

21

| 6. EMPLOYEE INFORMATION | | |
|-------------------------|-------|-------|
| | 2024 | 2023 |
| | £'000 | £'000 |
| STAFF COSTS | | |
| Salaries and wages | 248 | 194 |
| Social security costs | 22 | 18 |
| Pension costs | - | 4 |
| TOTAL | 270 | 216 |

No employees received emoluments exceeding £60,000 (2022-23: Nil). No trustee received any remuneration from the charity during the year (2022-23: Nil). No trustee expenses have been incurred (2022-23: Nil). An average of 6.0 staff (2022-23: 6.0) were employed during the year. There is no key management remuneration to disclose (2022-23: Nil) as only the Trustees are deemed key management.

7. FIXED ASSET INVESTMENTS

| | 2024 | 2023 |
|---|---------|----------|
| | £'000 | £'000 |
| Cost or valuation | | |
| At 1 April 2023 | 99,133 | 101,438 |
| Additions | 8,955 | 11,958 |
| Disposals | (6,189) | (11,826) |
| Cash movements | (1,360) | 257 |
| Net Investment gains/(losses) | 2,683 | (2,694) |
| Net Book Value as at 31 March 2024 | 103,222 | 99,133 |
| | 2024 | 2023 |
| | £'000 | £'000 |
| Fixed asset investments are represented by: | | |
| Fixed interest securities | 9,159 | 8,385 |
| Equity shares | 57,473 | 53,550 |
| Investment trusts and unit trust | 25,672 | 25,929 |
| Commodities | 2,361 | 1,352 |
| Cash for reinvestment | 8,557 | 9,917 |
| At 31 March 2024 | 103,222 | 99,133 |

Investments included in the above with a market value greater than 5% of the total portfolio market value at 31 March 2024 are as follows:

| | 2024 | 2023 |
|-----------------------------|--------|--------|
| | £'000 | £'000 |
| BNY Sustainable Glb Dynamic | 20,173 | 20,259 |
| Cash for reinvestment | 8,557 | 9,917 |

| 8. DEBTORS | | 2024 | 2023 |
|--|-------------|-------------------------|------------------|
| | | £'000 | £'000 |
| Debtors due within one year Due From Related Undertakings | | 2,343 | 1,479 |
| VAT Recoverable | | 2,343 3 | 1,479 |
| Prepayments and accrued income | | 312 | 252 |
| Total Debtors due within one year | | 2,658 | 1,734 |
| 9. CREDITORS | | 2024 | 2023 |
| | | £'000 | £'000 |
| Creditors due within one year | | | |
| Accruals | | 2,479 | 2,610 |
| Other Creditors | | 657 | 644 |
| Total Creditors due within one year | | 3,136 | 3,254 |
| | | | |
| 10. ANALYSIS OF THE NET ASSETS BETWEEN FU | INDS | | |
| | | Net | - |
| | | Current | Total at |
| | Investments | Assets/ | 31 March 2024 |
| | £'000 | (Liabilites) £'000 | £'000 |
| | | 2 000 | 2000 |
| Endowed Funds | 7,832 | (1,892) | 5,939 |
| Restricted Funds | 76,026 | 8,985 | 85,012 |
| Unrestricted Funds | 18,707 | (3,545) | 15,162 |
| Golden Jubilee National Hospital | 657 | (657) | - |
| Total 2024 | 103,222 | 2,891 | 106,113 |
| | | | |
| | | Net | |
| | | Current | Total at |
| | Invoctmente | Assets/ (Liabilites) | 31 March |
| | Investments | | 2023 |
| | £'000 | £'000 | £'000 |
| Endowed Funds | 6,754 | (1,316) | 5,438 |
| Restricted Funds | 69,894 | 11,324 | 81,218 |
| Unrestricted Funds | 21,841 | (4,034) | 17,807 |
| Golden Jubilee National Hospital | 644 | (644) | - |
| Total 2023 | 99,133 | 5,330 | 104,463 |

11. TAXATION

The charity is a registered charity, and as such is entitled to certain tax exemptions on income and profits from investments, and surpluses on any trading activities carried on in furtherance of the charity's primary objectives, if these profits and surpluses are applied solely for charitable purposes.

| | Balance as at 1 April 2023 £'000 | Receipts £'000 | Payments £'000 | Transfers £'000 | Investment Gain £'000 | Balance as at 31 March 2024 £'000 |
|--|--|-------------------|-------------------|--------------------|-----------------------------|---|
| Unrestricted Funds | 2 000 | 2 000 | 2 000 | 2 000 | 2 000 | 2 000 |
| Total Unrestricted Funds | | | | | | |
| rotal Unrestricted Funds | 17,807 | 649 | (4,027) | (294) | 1,027 | 15,162 |
| Restricted Funds | | | | | | |
| Advanced Practice | 147 | 4 | (9) | - | - | 142 |
| Arthritis | 250 | 9 | (4) | - | 17 | 272 |
| Baxter's Bequest | 345 | 13 | (4) | - | 23 | 377 |
| B-crf Comm + Non Comm Activity | 6,625 | 2,536 | (1,924) | (15) | 10 | 7,232 |
| B-crf Donations | 108 | 7 | (2) | - | - | 113 |
| Beatson Brachytherapy Beatson Wos Patient Centred | 54 153 | 3 | (4) (85) | - | - | 51 71 |
| Biochemistry Department | 186 | 3 14 | (5) | _ | - 12 | 207 |
| Blackwood Plastic Surg'y | 67 | 3 | (1) | _ | 4 | 73 |
| B'lee Blood Borne Viruses | 70 | 2 | - | _ | - | 72 |
| Blyth Research Fund | 87 | 2 | (8) | - | - | 81 |
| Breast Cancer 2000 | 99 | 2 | - | - | - | 101 |
| Camhs Endowment Fund | 56 | 3 | (1) | - | 4 | 62 |
| Cancer Network Educational | 97 | 5 | (20) | 1 | - | 83 |
| Childrens | 190 | 7 | (34) | - | 11 | 174 |
| Church Research Fund | 75 | 2 | (9) | - | - | 68 |
| Continence Service Training | 51 | 1 | (1) | - | - | 51 |
| Cont.prof.dev.gp's Wofscot | 99 61 | 2 | (40) | - | - | 101 22 |
| Covid 19 - Barclays Covid-19 Donations | 113 | 41 | (40) (19) | - | - | 135 |
| Cystic Fibrosis | 197 | 19 | (9) | _ | 13 | 220 |
| Day Release Psychiatry-wofs | 241 | 51 | (34) | _ | - | 258 |
| Day Surgery Unit | 71 | 3 | (1) | - | 5 | 78 |
| Dbar Rehab Research Fund | 64 | 1 | - | - | - | 65 |
| Dermatology | 48 | 2 | - | - | 3 | 53 |
| Diabetic | 186 | 8 | (2) | - | 12 | 204 |
| Directorate Of Med Education | 172 | 4 | (1) | - | - | 175 |
| Dr Barclay's Liver Research | 292 | 22 | (13) | - | - | 301 |
| Dr Gaya's Ibd Research | 57 | 2 | (10) | - | - | 49 |
| Early Breast Cancer Recurrance | 128 | 3 | (6) | - | - | 125 |
| East Renfrewshire Chcp Budget Education And Training | 27 191 | 7 | (60) (18) | 33 | - | 180 |
| Equipment Fund | 267 | 31 | (4) | _ | _ | 294 |
| Ermina Johnson Legacy | 269 | 7 | (1) | _ | _ | 275 |
| Eye Research | 86 | 3 | (1) | _ | 6 | 94 |
| Fleming | 47 | 2 | (1) | - | 3 | 51 |
| F.p. Training Fund | 137 | 4 | (1) | - | - | 140 |
| Friends Of Glasg. Cdm Prog. | 68 | 2 | (1) | - | - | 69 |
| Gartnavel Digestive Diseases | 82 | 29 | (13) | - | - | 98 |
| Gartnavel Hepatitis Research | 53 | 45 | (23) | - | - | 75 |
| Gei/ggh Eye Dept | 82 | 2 | (2) | - | - | 82 |
| General Physiotherapy | 57 | 4 | (1) | - | - | 60 |
| Ggc - Virology Fund Ggh B'chem Drug Investig | 379 118 | 14 3 | (2) | - | ı | 392 120 |
| Gghb Social Welfare | 2,504 | 92 | (1) (26) | _ | - 166 | 2,736 |
| Ggh-cr-uk In-house Projects Fu | 1,222 | 1,054 | (1,269) | 15 | 2 | 1,024 |
| Ggh Diabetic Research | 302 | 7 | (61) | - | - | 248 |
| Ggh Ediu General | 82 | 52 | (14) | - | - | 120 |
| Ggh Opthalmology Direct | 88 | 2 | (4) | - | - | 86 |
| Ggh Optometry | 74 | 16 | (3) | - | - | 87 |
| Ggh Pats + Staff Welfare | 152 | 4 | (1) | - | - | 155 |
| Ggh Radionuclide Service | 160 | 37 | 30 | - | - | 227 |
| Ggh-scottish Virology | 127 | 3 | (9) | - | - | 121 |
| Glasgow Emer Med Research Fnd | 50 65 | 1 | - (44) | - | - | 51 55 |
| Glas Interventional Rad Res | 65 | 1 | (11) | - | - | 55 |

| | Balance as at 1 April 2023 | Receipts | Payments | Transfers | Investment Gain | Balance as at 31 March 2024 |
|--|-------------------------------|-----------|-------------|---------------|--------------------|--------------------------------|
| Restricted Funds (Cont.) | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 |
| Glas Multiple Sclerosis Res | 114 | 29 | (4) | - | - | 139 |
| Graham Wilson Mem. Fd | 259 | 10 | (4) | - | 17 | 282 |
| Gri B'chem Clin Trials | 250 | 20 | (1) | - | - | 269 |
| Gri B'chem.trace Metals | 649 | (4) | (69) | - | 1 | 577 |
| Gri Cancer Fund | 2,011 | 73 | (61) | - | 132 | 2,155 |
| Gri Cardiology Fund | 79 | 2 | - | - | - | 81 |
| Gri Cardiology Prof.dept | 61 | 2 | (1) | - | - | 62 |
| Gri Chest + Heart Fund | 2,398 | 87 | (91) | - | 159 | 2,553 |
| Gri Clinical Apherisis Unit Gri Clinical Research Dev. | 73 | (77) | (422) | (2,629) | - | 75 224 |
| Gri Clinical Res. Project | 3,054 46 | (77) 5 | (122) | (2,628) | 4 | 231 51 |
| Gri Colorectal Fund | 51 | 2 | (1) | - | - | 52 |
| Gri Colorectal Fund Gri Critical Care Education | 85 | 3 | (1) | _ | _ | 87 |
| Gri Dermatology | 146 | 3 | (5) | _ | _ | 144 |
| Gri Endoscopy Workshop | 54 | 2 | - | _ | _ | 56 |
| Gri General Research | 102 | 4 | (4) | - | 7 | 109 |
| Gri Geriatric Cardiology | 132 | 5 | (52) | - | - | 85 |
| Gri Gynaecology Oncology | 74 | 2 | (33) | - | - | 43 |
| Gri Haematology Dept | 199 | 5 | (1) | - | - | 203 |
| Gri Intensive Care | 74 | 2 | (3) | (1) | - | 72 |
| Gri Kidney Unit | 185 | 9 | (4) | - | - | 190 |
| Gri Liver Research Fund | 131 | 4 | (1) | - | - | 134 |
| Gri Microbiology Dept | 489 | 12 | (33) | - | 1 | 469 |
| Gri M.p.millar General Fund | 928 | 34 | (38) | - | 61 | 985 |
| Gri Nuclear Cardiology Res | 81 | 14 | (20) | - | - | 75 70 |
| Gri Occupational Lung Disease | 74 | 5 | (1) | - | - | 78 |
| Gri Opthalmic Gri Renal Fund | 100 828 | 4 | (2) | - | 7 55 | 109 |
| Gri Respiratory Diseases Res | 23 | 30 40 | (2) | - | 55 | 911 63 |
| Gri Resuscitation | 49 | 39 | (35) | _ | _ | 53 |
| Gri Rheumatology Res. (madhok) | 294 | 7 | (2) | 67 | 1 | 367 |
| Gri St. Mungo Oncology Unit | 145 | 5 | (2) | - | 10 | 158 |
| Gri - The Ovarian Fund | 535 | 12 | (2) | _ | 1 | 546 |
| Gri Thrombosis Research | 233 | 10 | (8) | - | - | 235 |
| Gri Unscheduled Care Research | 68 | 21 | (7) | - | - | 82 |
| Gum (sandyford Place) | 65 | 1 | - | - | - | 66 |
| Haemophilia | 308 | 11 | (3) | - | 20 | 336 |
| Health Info And Volunteering | 73 | 2 | (15) | - | - | 60 |
| Health & Safety Service | 137 | 50 | (12) | - | - | 175 |
| Homeopathic Hospital Phase I | 1,758 | 65 | (20) | - | 116 | 1,919 |
| Infectious Dis. & Immuno | 61 | 5 | (1) | - | 4 | 69 |
| I.n.s. I.c. Mcwattie's Executr | 73 | 3 | (1) | - | 5 | 80 |
| Ins Neuroimaging Intensive Care Equipment | 57 104 | 1 | - (13) | - | 6 | 58 101 |
| Intensive Care Equipment Intensive Care Research | 143 | 4 6 | (13) (5) | - | 9 | 153 |
| Irh Cardiac Equip | 85 | 3 | (3) | _ | - | 88 |
| Irh Chest Unit | 69 | 2 | (1) | _ | _ | 70 |
| Irh Diabetic | 58 | 1 | - | _ | _ | 59 |
| Irh Haematology | 71 | 5 | (1) | _ | _ | 75 |
| Irh Macniven Bequest Fund | 85 | 2 | (1) | - | - | 86 |
| Irh Oncology | 107 | 4 | (5) | - | - | 106 |
| Irh Orthopedic | 156 | 4 | (1) | - | - | 159 |
| Irh Patient & Staff Amenities | 53 | 1 | - | - | - | 54 |
| Jean Smith Mcgeoch Fund | 53 | 3 | - | - | - | 56 |
| Jean W Brown Bequest | 300 | 22 | 82 | - | 1 | 405 |
| Joseph Cambell Bequest | 61 | 1 | - | - | - | 62 |
| Kenneth Kennedy Bequest | 55 | 4 | (1) | - | 4 | 62 |
| Legacy Frances Aranci | 133 | 4 | (1) | - | - | 136 |
| Legacy Patricia Clark | 86 | 2 | - (4) | - | - | 88 |
| Legacy Thomas/janet Lawrie Leukaemia & Cancer Res. | 70 910 | 2 113 | (1) (36) | - | - 61 | 71 1,048 |
| Lightburn Matron's Fund | 70 | 2 | (36) | - - | U I | 1,048 |
| LIGHTOUTH WALLOTT ST UTIL | 10 | ۷ | (4) | - | - | 00 |

| Restricted Funds (Cont.) £ 000 £ 0 | | Balance as at 1 April 2023 | Receipts | Payments | Transfers | Investment Gain | Balance as at 31 March 2024 |
|--|--------------------------------|-------------------------------|----------|----------|-----------|--------------------|--------------------------------|
| Maxwell Bequest 80 | Restricted Funds (Cont.) | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 |
| Medical Chemical Septime 63 | Margaret Bannerman Urquhart | 91 | 2 | - | - | - | 93 |
| Medical Cenetics | Maxwell Bequest | 80 | 4 | (1) | - | 5 | 88 |
| Mental Health Conference Fund 119 | Mclarty Bequest Levendale(sgh) | 63 | 1 | - | - | - | 64 |
| Metabloic 192 7 | Medical Genetics | 291 | 11 | (3) | - | 19 | 318 |
| Melealth/comm/pc/cant. Rad 69 | Mental Health Conference Fund | 119 | 14 | (11) | - | - | 122 |
| M. Mauris Equest 175 | | | | | - | 13 | 206 |
| Ms Muris Bequest 175 6 (7) - 12 186 Neurology Dept donations 150 4 (3) - - 98 Neurology Dept donations 150 4 (3) - - 151 Neurosurgical Equip Fund 109 3 - - - 151 Neurosurgical Equip Fund 109 3 - - - 172 Ng Breme Endocrine Research 93 9 (61) - - 41 Ng Breme Tinating-deucation 553 2 (11) - 1 623 Ngt Cap + Rev Initiatives 586 14 (7) - 1 594 Ng Breme Tinating-deucation 553 80 111 - 1 623 Ngt Cap + Rev Initiatives 586 14 (7) - 1 623 Ngt Cap + Reven Initiatives 586 14 (7) - 1 623 Ngt Cap - Stand | • | | | | - | - | |
| Neurolanaesthesia Research Fun 96 2 - - 98 98 150 4 (3) - - 151 151 151 152 | • | | | | - | | |
| Neurology Dept.donalions 150 | · | | | (7) | - | 12 | |
| Neurosurgical Equip Fund 109 3 | | | | - (2) | - | - | |
| Ng Alberosclerosis-lipid Resch 169 | | | | (3) | - | - | |
| Ng Bchem Lip-fatacid Hith-dise 101 2 (63) - - 41 Ng Bchem Lip-fatacid Hith-dise 101 2 (63) - - 40 Ng Bchem Lip-fatacid Hith-dise 105 2 (11) - 1 56 Ng Bchem I Training-deucation 558 80 (11) - 1 594 Ng Chap Fave I Intalities 586 14 (7) - 1 594 North Glas Lyle's Executry 600 22 (17) - 3 3 North Glas Lyle's Executry 600 22 (61) - - - 64 Obstetric Gg Equipment 122 2 (61) - - - 64 Obstetric Gg Equipment 122 2 (61) - - - 22 Optimal Collega 2 0 1 - - 22 22 Optimal Collega 2 2 3 (1 - | 3 | | | - (4) | - | - | |
| Ng Bchem Lip-Fatacid Hilth-dise 101 | | | | | - | - | |
| Ng-Prichem Metabolism Research 55 2 (1) - - 56 Ng-B'chem Training'education 553 80 (11) - 1 623 Ng-Cap + Rev Initiatives 586 14 (7) - 1 594 Nnch Glast Lyfe's Executry 600 22 (17) - 3 644 Noth Glast Lyfe's Executry 600 22 (217) - - 64 Obstetin Gg Equipment 122 2 (61) - - - 64 Obstetin Gg Equipment 122 2 (61) 3 - - 2278 Opthalmology 50 2 (3) - - 2278 Opthalmology Gardiner L'ship 305 2 (3) - - 202 Pact Path Dept, Research 73 33 (1) - 5 80 Peter Spul Endowment Fund 95 40 (2) (4) (2) 10 45< | 5 | | | ` , | - | - | |
| Ng Bréhem Training/education 553 80 (11) - 1 623 Ngt Cap + Rev Iniliatives 5586 14 (7) - 1 594 Ns Charity Trust Recovery - 441 (438) - - 3 North Giles Lyle's Executry 600 22 (17) - 39 644 Nthh. Gilw. Nurses/nurse Train. 63 1 - - - 64 Obstric Gg Equipment 122 20 (61) - - 63 Octu General 270 11 (3) - - 63 Ophthalmology 50 2 (3) - - 202 Overseas Support & Training 206 8 (12) - - 202 Pede Stirling Stobhill Legacy 456 10 (2) - 1 465 Peter Stirling Stobhill Legacy 127 3 (45) - - 85 Plumpton Cburn Plastic </td <td></td> <td></td> <td></td> <td>` ,</td> <td>-</td> <td>-</td> <td></td> | | | | ` , | - | - | |
| Ng1 Cap + Rev Initiatives 586 | _ | | | | - | - | |
| Nh Charity Trust Recovery - 441 (438) - - 3 644 North Glas Lyles Executry 603 1 - - - 64 Obstetric Gg Equipment 122 2 (61) - - 63 Octu General 270 11 (3) - - 278 Ophthalmology 50 2 (3) - - 278 Ophthalmology 50 2 (3) - - 202 Overseas Support & Training 206 8 (12) - - 202 Pathology Gardiner L'ship 335 12 (4) - 22 365 Peter String Stobhill Legacy 456 10 (2) - 1 465 Peter String Stobhill Legacy 127 3 (45) - - 92 Phenylkelonuria 98 4 (2) 6 69 - - 92 Plump | _ | | | ` , | - | 1 | |
| North Glas Lyte's Executry 600 22 (17) - 39 644 Nrth. Glw. Nursesinurse Train. 63 1 - - 64 Obstetire Gg Equipment 122 2 (61) - - 63 Octu General 270 11 (3) - 278 Octu General 270 11 (3) - 278 Octu General 270 11 (3) - 3 Octu General 270 11 (3) - 3 Optimalmology 50 2 (3) 3 - 3 Optimalmology 50 2 (3) 3 - 3 Optimalmology 50 2 (3) - - 202 Paed. Path Dept. Research 73 3 (1) - 5 80 Optimalmology 456 10 (2) - 1 465 Peter Stirling Stobhill Legacy 456 10 (2) - 1 465 Peter Stirling Stobhill Legacy 456 10 (2) - 1 465 Peter Stirling Stobhill Legacy 456 10 (2) - 7 107 Physical Activity Staff Legacy 127 3 (45) - 5 85 Plumpton Cburn Plastic 863 32 (9) - 57 943 Plumpton Cburn Plastic 863 32 (9) - 57 943 Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 288 7 (1) - 92 1,506 Ceulu Coronary Care Endowment 90 2 (2) - 90 Ceulu Coronary Care Endowment 90 2 (2) - 90 Ceulu Gen Pats + Staff Welfare 50 1 - - 91 Ceul Renal Unit Fund - 131 - - 131 Quality-serv Improvement Woscc 583 13 (3) - - 61 Rah Haematology 62 2 (4) - 60 Rah Hwrs Equip 83 2 (1) - - 84 Rah Surgical Research Fund 83 60 (49) 1 - 78 Rah Surgical Research Fund 4,330 176 (283) - 3 4,541 Research & Travel 1,058 40 (15) - 1,151 Research & Education (F.p. 94 2 (2) - 11 Research & Education (F.p. 94 2 (2) - 11 Research & Education (F.p. 94 2 (2) - 11 Research & Education (F.p. 94 2 (2) - 11 Research & Education (F.p. 94 2 (2) - 1 Research And Development 1,553 13 (4) (5) (5) (5) (3) Research Holdevelopment 1,553 (3) (54) (1) (5) (5) (3) Research Mol D | | 300 | | | - | ı | |
| NHTh, Glw, Nurses/nurse Train. 63 1 - - 64 63 Obstetric Gg Equipment 122 2 (61) - - 63 Octu General 270 111 (3) - - 278 Ophthalmology 50 2 (3) - 3 52 Overseas Support & Training 206 8 (12) - - 202 Pade, Path Dept. Research 73 3 (1) - 5 80 Pathology Gardiner L'ship 335 12 (4) - 22 365 Peter Striling Stobhill Legacy 456 10 (2) - 1 465 Peter Rpu Endowment Fund 95 6 (9) - - 92 Phenyliketonuria 98 4 (2) - 7 107 Physical Activity Staff Legacy 127 3 (4) (2) - 7 107 Pollotacy Staff Call | - | - 600 | | ` , | - | 30 | |
| Obstetric Gg Equipment 122 2 (61) - - 63 Octu General 270 11 (3) - - 278 Operseas Support & Training 206 8 (12) - - 202 Paed. Path Dept. Research 73 3 (11) - 5 305 Path Clogy Gardiner L'ship 335 12 (4) - 22 365 Peter Stirling Stobhill Legacy 456 10 (2) - 1 465 Peter Stirling Stobhill Legacy 456 10 (2) - 1 465 Peter Stirling Stobhill Legacy 157 6 (9) - - 92 Phenylkerbourdia 98 4 (2) - 7 107 Physical Activity Staff Legacy 127 3 (455) - - 85 Plumpton C'burn Plastic 863 32 (9) - 7 107 Pybil Geguest (rena | | | | (17) | - | 39 | |
| Oct General 270 11 (3) - - 278 Ophthalmology 50 2 (3) - 3 52 Overseas Support & Training 206 8 (12) - - 202 Pade, Path Dept. Research 73 3 (1) - 5 80 Pathology Gardiner L'ship 335 12 (4) - 22 365 Peter Stirling Stobhill Legacy 456 10 (2) - 1 465 Petry Endeowment Fund 95 6 (9) - 92 2 Phenylketonuria 98 4 (2) - 7 107 Physical Activity Staff Legacy 127 3 (45) - - 85 Plumpton Cburn Plastic 863 32 (9) - 57 943 Pollo Scrad Gp Educ W05 288 7 (1) - - 29 4 66 60 22 | | | | (61) | - | _ | |
| Ophthalmology 50 2 (3) - 3 52 Overseas Support & Training 206 8 (12) - - 202 Paed, Path Dept, Research 73 3 (1) - 5 80 Pathology Gardiner L'ship 335 12 (4) - 22 365 Peter Spu Endowment Fund 95 6 (9) - - 92 Phenylketonuria 98 4 (2) - 7 107 Physical Activity Staff Legacy 127 3 (45) - - 92 Plumpton C'burn Plastic 863 32 (9) - 57 943 Pollo Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 288 7 (1) - - 92 1,506 Qeu Coronary Care Endowment 90 2 (27) - 92 1,506 Qeu Hosen Set Staff | | | | ` , | _ | _ | |
| Overseas Support & Training 206 8 (12) - - 202 Paed, Path Dept. Research 73 3 (1) - 5 80 Pathology Gardiner L'ship 335 12 (4) - 22 365 Peter Stirling Stobhill Legacy 456 10 (2) - 1 465 Pet Ryb Endowment Fund 95 6 (9) - - 92 Phenylketonuria 98 4 (2) - 7 107 Phenylketonuria 863 32 (9) - 57 943 Pollox Beguest (renal) 594 42 (6) - 40 670 Polk Grad Gp Educ W05 288 7 (11) - - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Ceuh Coronary Care Endowment 90 2 (2) - - 90 Qeuh Renal Unit Fund | | | | ` , | _ | 3 | |
| Paed. Path Dept. Research 73 3 (1) - 5 80 Pathology Gardiner L'ship 335 12 (4) - 22 365 Peter String Stobhill Legacy 466 10 (2) - 1 465 Pet Rpu Endowment Fund 95 6 (9) - - 92 Phenylketonuria 98 4 (2) - 7 107 Physical Activity Staff Legacy 127 3 (45) - - 85 Plumpton C'burn Plastic 863 32 (9) - 57 943 Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 288 7 (1) - - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Qeun Coronary Care Endowment 90 2 (2) - - 9 Qeu Renal Unif Fund | | | | | _ | - | |
| Pathology Gardiner L'ship 335 12 (4) - 22 365 Peter Stirling Stobhill Legacy 456 10 (2) - 1 465 Pet RP Landowment Fund 95 6 (9) - 7 107 Phenylketonuria 98 4 (2) - 7 107 Physical Activity Staff Legacy 127 3 (45) - - 85 Plumpton C'burn Plastic 863 32 (9) - 57 943 Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 288 7 (1) - - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Qeuh Coronary Care Endowment 90 2 (2) - - 51 Qeuh Gen Pats + Staff Welfare 50 1 - - - 51 Qeuh Gen Pats + Staff | | | | | _ | 5 | |
| Peter Stirling Stobhill Legacy 456 10 (2) - 1 465 Pet Rpu Endowment Fund 95 6 (9) - - 92 Phenylketonuria 98 4 (2) - 7 107 Physical Activity Staff Legacy 127 3 (45) - - 85 Plumpton C'burn Plastic 863 32 (9) - 57 943 Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Cp Educ W05 288 7 (1) - - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Qeuh Coronary Care Endowment 90 2 (2) - 90 1,506 Qeuh Renal Unit Fund - 131 - - - 131 Qeuh Renal Unit Fund - 131 - - - 61 Rah Diabetes Research < | • | | | ` ' | _ | | |
| Pet Rpu Endowment Fund 95 6 (9) - - 92 Phenylketonuria 98 4 (2) - 7 107 Physical Activity Staff Legacy 127 3 (45) - - 88 Plumpton C'burn Plastic 863 32 (9) - 57 943 Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 288 7 (1) - - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Qeu Coronary Care Endowment 90 2 (2) - 90 Qeu M Coronary Care Endowment 90 2 (2) - 90 Qeu M Coronary Care Endowment 90 2 (2) - 90 Qeu M Coronary Care Endowment 90 2 (2) - - 10 Qeu M Caronary Care Endowment Wosco 583 133 | | | | | _ | | |
| Phenylketonuria 98 4 (2) 7 107 Physical Activity Staff Legacy 127 3 (45) - 85 Plumpton C'burn Plastic 863 32 (9) - 57 943 Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 288 7 (1) - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Geuh Coronary Care Endowment 90 2 (2) - - 90 Qeuh Gen Pats + Staff Welfare 50 1 - - - 51 Qeun Renal Unit Fund - 131 - - - 131 Quality+serv Improvement Wosco 583 13 (3) - 1 - - 61 Rah Diabetes Research 60 4 (4) - - 60 Rah Legastition Training Fun 66 | | | | | _ | · - | |
| Physical Activity Staff Legacy 127 3 (45) - - 85 Plumpton C'burn Plastic 863 32 (9) - 57 943 Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 288 7 (1) - - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Qeuh Gronary Care Endowment 90 2 (2) - 90 20 Qeuh Gen Pats + Staff Welfare 50 1 - - - 51 Qeuh Renal Unit Fund - 131 - - - 51 Qeuh Renal Unit Fund - 131 - - - 51 Qual Renal Unit Fund - 0 2 (1) - - 61 Rah Baesarch Staff Welfare 60 2 (4) - - 60 Rah Teat Wirstag | • | | | | _ | 7 | |
| Plumpton C'burn Plastic 863 32 (9) - 57 943 Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 228 7 (1) - - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Qeuh Coronary Care Endowment 90 2 (2) - - 90 Qeuh Renal Unit Fund - 131 - - - 131 Qeuh Renal Unit Fund - 131 - - - 131 Quality+serv Improvement Woscc 583 13 (3) - 1 594 Rah Diabetes Research 60 2 (1) - - 61 Rah Haematology 62 2 (4) - - 76 Rah Surgical Research Fund 83 2 (1) - - 78 Rah Wrvs Equip 83 | - | | | | _ | _ | |
| Pollok Bequest (renal) 594 42 (6) - 40 670 Post Grad Gp Educ W05 288 7 (1) - - 294 Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Geuh Coronary Care Endowment 90 2 (2) - 9 90 Qeuh Gen Pats + Staff Welfare 50 1 - - - 131 Qeuh Renal Unit Fund - 131 - - - 131 Quality+serv Improvement Woscc 583 13 (3) - 1 594 Rah Diabetes Research 60 2 (1) - - 61 Rah Haematology 62 2 (4) - - 60 Rah Haematology 62 2 (4) - - 60 Rah Surgical Research Fund 83 2 (1) - - 78 Rah Surgical Research Fund 4,330 </td <td></td> <td>863</td> <td>32</td> <td>` '</td> <td>_</td> <td>57</td> <td>943</td> | | 863 | 32 | ` ' | _ | 57 | 943 |
| Price Bequest Wards 6/7 1,391 50 (27) - 92 1,506 Qeuh Coronary Care Endowment 90 2 (2) - - 90 Qeuh Gen Pats + Staff Welfare 50 1 - - - 51 Qeuh Renal Unit Fund - 131 - - - 131 Quality+serv Improvement Woscc 583 131 (3) - 1 594 Rah Diabetes Research 60 2 (1) - - 61 Rah Haematology 62 2 (4) - - 60 Rah-resuscitation Training Fun 66 60 (49) 1 - 60 Rah-resuscitation Training Fun 83 6 (23) - - 66 Rah Wrvs Equip 83 2 (1) - - 48 Rebus Equip 4,330 176 (283) - 320 4,543 Reid Bequest - Opthalmic <td< td=""><td></td><td>594</td><td>42</td><td>, ,</td><td>-</td><td>40</td><td>670</td></td<> | | 594 | 42 | , , | - | 40 | 670 |
| Qeuh Coronary Care Endowment 90 2 (2) - - 90 Qeuh Gen Pats + Staff Welfare 50 1 - - - 51 Qeuh Renal Unit Fund - 131 - - - 131 Quality+serv Improvement Wosc 583 13 (3) - 1 594 Rah Diabetes Research 60 2 (4) - - 61 Rah Haematology 62 2 (4) - - 60 Rah-resuscitation Training Fun 66 60 (49) 1 - - 68 Rah Surgical Research Fund 83 6 (23) - - 66 Rah Wrvs Equip 83 6 (23) - - 84 Rbm Cancer Fund 4,330 176 (283) - 320 4,543 Reid Bequest - Opthalmic 355 13 (4) - - 4 Reid Bequest - Opthalmic | Post Grad Gp Educ W05 | 288 | 7 | (1) | - | - | 294 |
| Qeuh Gen Pats + Staff Welfare 50 1 - - 51 Qeuh Renal Unit Fund - 131 - - - 131 Quality+serv Improvement Woscc 583 13 (3) - 1 594 Rah Diabetes Research 60 2 (1) - - 60 Rah Haematology 62 2 (4) - - 60 Rah-resuscitation Training Fun 66 60 (49) 1 - 78 Rah Surgical Research Fund 83 6 (23) - - 66 Rah Wrvs Equip 83 2 (1) - - 66 Rah Wrvs Equip 4330 176 (283) - 320 4,543 Rebrid Bequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 | Price Bequest Wards 6/7 | 1,391 | 50 | (27) | - | 92 | 1,506 |
| Qeuh Renal Unit Fund - 131 - - - 131 594 584 686 680 2 11 - - 61 61 680 <td>Qeuh Coronary Care Endowment</td> <td>90</td> <td>2</td> <td>(2)</td> <td>-</td> <td>-</td> <td>90</td> | Qeuh Coronary Care Endowment | 90 | 2 | (2) | - | - | 90 |
| Quality+serv Improvement Woscc 583 13 (3) - 1 594 Rah Diabetes Research 60 2 (1) - - 61 Rah Haematology 62 2 (4) - - 60 Rah-resuscitation Training Fun 66 60 (49) 1 - 78 Rah Surgical Research Fund 83 6 (23) - - 66 Rah Wrvs Equip 83 2 (1) - - 66 Rah Wrvs Equip 83 2 (1) - - 66 Rah Wrvs Equip 83 2 (1) - - 66 Rah Wrvs Equip 4,330 176 (283) - 320 4,543 Rebd Gequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 | Qeuh Gen Pats + Staff Welfare | 50 | 1 | - | - | - | 51 |
| Rah Diabetes Research 60 2 (1) - - 61 Rah Haematology 62 2 (4) - - 60 Rah-resuscitation Training Fun 66 60 (49) 1 - 78 Rah Surgical Research Fund 83 6 (23) - - 66 Rah Wrvs Equip 83 2 (1) - - 66 Rbmh Cancer Fund 4,330 176 (283) - 320 4,543 Reid Bequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 | Qeuh Renal Unit Fund | - | 131 | - | - | - | 131 |
| Rah Haematology 62 2 (4) - - 60 Rah-resuscitation Training Fun 66 60 (49) 1 - 78 Rah Surgical Research Fund 83 6 (23) - - 66 Rah Wrvs Equip 83 2 (1) - - 84 Rbmh Cancer Fund 4,330 176 (283) - 320 4,543 Reid Bequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 <td>Quality+serv Improvement Woscc</td> <td>583</td> <td>13</td> <td>(3)</td> <td>-</td> <td>1</td> <td>594</td> | Quality+serv Improvement Woscc | 583 | 13 | (3) | - | 1 | 594 |
| Rah-resuscitation Training Fun 66 60 (49) 1 - 78 Rah Surgical Research Fund 83 6 (23) - - 66 Rah Wrvs Equip 83 2 (1) - - 84 Rbmh Cancer Fund 4,330 176 (283) - 320 4,543 Reid Bequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 3 457 Rhsc Epilepsy Genetics | | | | (1) | - | - | 61 |
| Rah Surgical Research Fund 83 6 (23) - - 66 Rah Wrvs Equip 83 2 (1) - - 84 Rbmh Cancer Fund 4,330 176 (283) - 320 4,543 Reid Bequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 3 119 Royal Sam Women's Health <td< td=""><td>Rah Haematology</td><td>62</td><td>2</td><td>(4)</td><td>-</td><td>-</td><td>60</td></td<> | Rah Haematology | 62 | 2 | (4) | - | - | 60 |
| Rah Wrvs Equip 83 2 (1) - - 84 Rbmh Cancer Fund 4,330 176 (283) - 320 4,543 Reid Bequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150< | _ | | | ` , | 1 | - | |
| Rbmh Cancer Fund 4,330 176 (283) - 320 4,543 Reid Bequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 | _ | | | | - | - | |
| Reid Bequest - Opthalmic 355 13 (4) - 24 388 Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 | | | | | - | - | |
| Renal Research & Travel 1,056 40 (15) - 70 1,151 Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - - 91 S.gen.spinal Injuries 418 | | • | | ` ' | - | | • |
| Renal Unit 168 6 (2) - 11 183 Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - - 91 S.gen.spinal Injuries 418 31 (135) - - 91 Sgh Centre-diabetes & Metab 82 | · | | | | - | | |
| Research And Development 1,253 1,038 (541) 2,628 3 4,381 Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - - - 87 Sgh Haematology Dept | | • | | - | - | | • |
| Research & Education(f.p 94 2 (2) - - 94 Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Haematology Dept Fd. 143 3 - - - - 146 | | | | | - | | |
| Resuscitation Course 65 37 (54) 1 3 52 Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Haematology Dept Fd. 143 3 - - - - 146 | • | • | | | 2,028 | 3 | • |
| Rhc Theatre Project 406 21 (8) - 38 457 Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - 146 | ` . | | | | - 1 | - 2 | |
| Rhsc Epilepsy Genetics 118 14 (20) - 7 119 Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - 146 | | | | - | - | | |
| Roma Allocn. S.e. Chcp 76 3 (1) - 5 83 Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - 146 | - | | | | _ | 7 | |
| Royal Sam Women's Health 5,724 209 (59) - 379 6,253 Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - 146 | | | | - | _ | , 5 | |
| Rvs Gifting 150 4 (1) - - 153 Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - 146 | • | | | | _ | | |
| Sannino Orthopaedic 107 4 (1) - 7 117 S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - 146 | • | | | ` ' | - - | - | , |
| S.gen.clin.trials Research 117 3 (29) - - 91 S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - 146 | _ | | | , , | _ | 7 | |
| S.gen.spinal Injuries 418 31 (135) - 1 315 Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - - 146 | • | | | | _ | - | |
| Sgh Centre-diabetes & Metab 82 5 - - - 87 Sgh Haematology Dept Fd. 143 3 - - - 146 | • | | | ` ' | - | 1 | |
| Sgh Haematology Dept Fd. 143 3 146 | | | | - | - | - | |
| | _ | | | - | - | - | 146 |
| | Sgh Headache Clinic | 175 | 8 | (4) | - | - | 179 |

| | Balance as at 1 April 2023 | Receipts | Payments | Transfers | Investment Gain | Balance as at 31 March 2024 |
|--|-------------------------------|----------|--------------|---------------|--------------------|--------------------------------|
| Restricted Funds (Cont.) | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 |
| Sgh Ins Nurses Wd.61 Equipment | 42 | 12 | (4) | - | - | 50 |
| Sgh Main X-ray Dept Educ | 67 | 32 | (16) | - | - | 83 |
| Sgh - Mouth Cancer | 68 | 2 | (1) | - | - | 69 |
| Sgh M.s. Clinic Fund | 66 | 2 | (1) | - | - | 67 |
| Sgh Neuroimaging Res & Educ | 92 | 2 | (1) | - | - | 93 |
| Sgh Neurosurgery Dept. Fund | 144 | 4 | (3) | - | - | 145 |
| Sgh Neuro Vascular Develop | 70 | 2 | (5) | - | - | 67 |
| Sgh Neurovascular Research | 115 | 4 | (26) | - | - | 93 |
| Sgh Nuclear Med. Fund | 206 | 15 | (14) | - | - | 207 |
| Sgh Orthopaedic Fund | 69 | 11 | (1) | - | - | 79 60 |
| Sgh Rheumatology Dept Fd Sgh Yamanouch | 105 82 | 2 63 | (38) (1) | - | - | 69 144 |
| S Glasgow Hosps Equipt | 775 | 29 | (20) | - | - 51 | 835 |
| Sg Neuro-oncology | 166 | 4 | (9) | _ | - | 161 |
| Sg Staff Gym | 354 | 5 | (355) | _ | _ | 4 |
| S'hill Gyn-laser & Oncology | 172 | 5 | (34) | _ | _ | 143 |
| S'hill Haematology Dept. | 101 | 3 | (1) | _ | _ | 103 |
| S'hill Patients & Staff | 97 | 2 | - | _ | _ | 99 |
| S'hill Rheumatic Dis.res | 130 | 7 | (7) | (67) | _ | 63 |
| Sht Allocation | 49 | 2 | (4) | | 3 | 50 |
| Skea Legacy Renal-transplant | 106 | 3 | (1) | - | - | 108 |
| Stb-emergency Retrieval Ser | 66 | 2 | (1) | - | - | 67 |
| Transplant + Renal Failure | 112 | 4 | (7) | - | - | 109 |
| Tset Account | 144 | 128 | (12) | - | - | 260 |
| Ukneqas-cardiac Markers Vic Breast Cancer Research | 146 55 | 153 1 | (183) (2) | - | _ | 116 54 |
| Vic Cancer Research Fd. | 263 | 10 | (3) | _ | 17 | 287 |
| Vic Diabetic Development Fund | 61 | 2 | (3) | _ | - | 60 |
| Vic Haematology Lab.fund | 64 | 3 | (3) | - | - | 64 |
| Vic Orthopaedic Fund | 57 | 1 | - | - | - | 58 |
| Vic. Pathology Laboratory Fund | 249 | 28 | (3) | - | - | 274 |
| Vic Respiratory Fund | 50 | 3 | (5) | - | - | 48 |
| Vic Resuscitation Training | 49 | 65 7 | (94) | (1) | - | 19 |
| Vict. G.macfarlane Victoria Student Nurses | 171 72 | 3 | (2) | - | 11 5 | 187 79 |
| Victoria Student Nurses Vic Wards 20 & 21 Fund | 83 | 3 | (1) (1) | _ | 5 | 90 |
| Vol Alexander S Young Legacy | 51 | 1 | - | _ | - | 52 |
| Vol Cancer Care | 62 | 61 | (2) | 1 | _ | 122 |
| Ward 1e Cardiology | 109 | 2 | - | _ | _ | 111 |
| Ward 60 Institute Sgh | 66 | 2 | (5) | - | - | 63 |
| Ward 6a | 78 | 4 | (1) | - | 5 | 86 |
| Ward 7a | 60 | 2 | (1) | - | 4 | 65 |
| West Radiopharmacy Research | 56 | 2 | - (1.1) | - | - | 58 207 |
| Wig Asthma Research Wig Beatson Oncology | 302 120 | 18 5 | (14) (24) | _ | <u>'</u> | 307 101 |
| Wig Bone Research | 103 | 3 | (2) | _ | _ | 104 |
| Wig Breast Unit | 125 | 3 | (1) | _ | _ | 127 |
| Wig Cancer | 881 | 33 | (9) | - | 58 | 963 |
| Wig Cardiol. (hamilton/hastie) | 394 | 14 | (4) | - | 26 | 430 |
| Wig Dialysis Pats Amenity | 69 | 2 | (3) | - | - | 68 |
| Wig Gastro-intestinal | 106 | 11 | - (0) | - | - | 117 |
| Wig Gastro/ology Research | 65 150 | 6 65 | (3) | - | - | 68 |
| Wig / Ggh Imaging Direct Wig Haematology Educat | 159 339 | 65 33 | (4) (12) | _ | - 1 | 220 361 |
| Wig Joint Cardiac Research | 22 | 171 | (86) | _ | | 107 |
| Wig Nuclear Med Research | 60 | 1 | (2) | - | - | 59 |
| Wig Opthalmology Fund | 128 | 3 | (1) | - | - | 130 |
| Wig Plastic | 303 | 11 | (12) | - | 20 | 322 |
| Wig Renal Unit Fund | 138 | 3 | (14) | - | - | 127 |
| Wig Respiratory Res | 129 | 7 | (6) | - | - | 130 |
| Wig Rheum.arthritis Res. | 124 | 3 | 5 | - | - | 132 |
| Wig Scanner Fund Wig Skin Cancer Research | 87 57 | 3 9 | (1) | - | 6 | 95 65 |
| Wig Skin Cancer Research Wig Stroke Unit Research | 286 | 9 53 | (1) (27) | - - | - - | 312 |
| Wig-west Glw. Dermatology | 189 | 68 | (27) (7) | - | - | 250 |
| J | | | (- / | | | |

12. FUNDS

| | Balance as at 1 April 2023 | Receipts | Payments | Transfers | Investment Gain | Balance as at 31 March 2024 |
|--------------------------------|-------------------------------|----------|----------|-----------|--------------------|-----------------------------|
| Restricted Funds (Cont.) | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 |
| Wilson Watt Bequest | 508 | 18 | (5) | - | 34 | 555 |
| W.of Scot.breast Screening Ed. | 46 | 1 | 4 | - | - | 51 |
| Wos Cystic Fibrosis Unit | 167 | 41 | (17) | - | - | 191 |
| Wos Lung Cancer Research | 57 | 1 | - | - | - | 58 |
| Y'hill Staff Gym | 225 | 6 | (226) | - | 9 | 14 |
| Yorkhill Tct Fund | 247 | 9 | (7) | - | 16 | 265 |
| Other | 9,590 | 685 | (907) | 259 | 182 | 9,809 |
| Total Restricted Funds | 81,218 | 9,589 | (8,710) | 294 | 2,621 | 85,012 |

The titles of the individual funds are indicative of the particular specialty, department, hospital or research activity that they support. They fall into two broad categories - funds received by way of legacies or substantive donations to support particular specialties/developments/research activities. Alternatively they are funds of a custodian nature established at the request of designated fundholders and controlled by them on an operational basis, but subject to the general oversight of the Trustees. Custodian funds are mainly research orientated but also include minor amenity funds operated for specific wards/departments.

Abbreviations used above are as follows: GRI - Glasgow Royal Infirmary, PRMH - Princess Royal Maternity Hospital, WIG - Western Infirmary Glasgow, GGH - Gartnavel General Hospital, VI - Victoria Infirmary, SGH - Southern General Hospital, QMH - Queen Mothers Hospital, RHSC - Royal Hospital for Sick Children, RAH - Royal Alexandra Hospital, IRH - Inverclyde Royal Hospital, DBAR - Dykebar Hospital, INS - Institute of Neurological Sciences

Endowment Funds

| | Balance as at 1 April 2023 £'000 | Receipts £'000 | Payments £'000 | Transfers £'000 | Investment Gain £'000 | Balance as at 31 March 2024 £'000 |
|---------------------------------|--|-------------------|-------------------|--------------------|-----------------------------|---|
| Other | 76 | 1 | (1) | - | 7 | 83 |
| Broomhill Sayacs | 30 | 1 | - | - | 2 | 33 |
| Catherine Mcphail Craig Bequest | 444 | 17 | (6) | - | 29 | 484 |
| Eye Infirmary | 34 | 1 | - | - | 2 | 37 |
| Glasgow Royal Infirmary | 1,158 | 42 | (12) | - | 77 | 1,265 |
| Ins Keeling Bequest | 48 | 2 | (1) | - | 3 | 52 |
| Macfarlane Fund | 1,496 | 54 | (15) | - | 99 | 1,634 |
| M.keeling (vict.ward 5a) | 51 | 3 | (1) | - | 3 | 56 |
| Royal Beatson | 81 | 3 | (1) | - | 5 | 88 |
| Sir J.Andersons Fund | 1,033 | 39 | (11) | - | 68 | 1,129 |
| Western Infirmary | 947 | 34 | (10) | - | 63 | 1,034 |
| Wig Group Nursing Sch | 40 | 1 | - | - | 3 | 44 |
| Total | 5,438 | 198 | (58) | - | 361 | 5,939 |

Endowment Funds are established when funding is received with the proviso that the capital is to be preserved and only the revenue spent. The revenue generated by the Anderson and Macfarlane Funds is utilised to support research activity at the Glasgow Royal Infirmary.

DocuSign Envelope ID: 10B157DC-35FE-493E-A984-8D57A4A17521

| 13. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES | | |
|---|---|---|
| | 2024 | 2023 |
| | £'000 | £'000 |
| Continuing Activities | | |
| Net Income/(Expenditure) for the Year (Gains)/Losses on Investments Investment (Income) Increase in Debtors Decrease in Creditors | 1,650 (4,009) (3,133) (920) (118) | (3,334) 2,289 (2,591) (962) (808) |
| Net Cash Used In Operating Activities | (6,530) | (5,406) |
| 14. RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN FUNDS | | |
| Decrease in cash in year | (3,481) | (2,851) |
| Cash used to (decrease)/increase short term deposits | (1,360) | 257 |
| Movement in cash in year per statement of cash flows | (4,841) | (2,594) |
| 15. FINANCIAL INSTRUMENTS Financial assets at fair value | 103,222 | 99,133 |

Financial assets measured at fair value relate to investments held within non-current assets on the balance sheet. These are mainly comprised of listed investments and bonds, with further information disclosed in Note 7 Fixed Asset Investments.

16. RELATED PARTY TRANSACTIONS

| Related Party | Related Party Transactions | Detail of Related Party |
|---|---|---|
| NHS Greater Glasgow and Clyde | Payroll recharges of £270,000 and year-end debtor due to the Charity of £2,343,000. | The Charity's ultimate parent and 100% controlling party is NHSGGC. |
| East Dunbartonshire Integration Joint Board | Charitable funding of £32,000 was provided for East Dunbartonshire IJB in 2023-24. | Ms J Forbes, Non-Executive Member also a Chair of East Dunbartonshire Integration Joint Board., Ms K Miles and Mr I Ritchie, Non-Executive Members, were also members of East Dunbartonshire Integration Joint Board. |
| East Renfrewshire Integration Joint Board | Charitable funding of £27,000 was provided for East Renfrewshire IJB in 2023-24. | Ms K Pragnell, Non-Executive Member was also a Vice Chair of East Renfrewshire Joint Integration Joint Board. Ms J Forbes, Ms A-M Monaghan, Ms D Foy, Ms M Ashraf, Non-Executive Members, were also members of East Renfrewshire Integration Joint Board. |
| Glasgow City Integration Joint Board | Charitable funding of £209,000 was provided for Glasgow City IJB in 2023-24. | Mr S Carr, (left 31/08/2023) Non-Executive Member was also a Vice Chair of Glasgow City Integration Joint Board. Mr A Cowan, Mr F Sheenan (left 31/05/24), Mr G Haddock OBE, Mr D Gould, Ms A-M Monaghan, Mr C Cunningham, Ms R Sweeney and Mr C Vincent Non-Executive Members, and Mr J Matthews OBE, Vice-Chair, were also members of Glasgow City Integration Joint Board. |
| Inverclyde Integration Joint Board | Charitable funding of £28,000 was provided for Inverclyde IJB in 2023-24. | Mr A Cowan, Non-Executive Member was also a Vice Chair of Inverclyde Integration Joint Board. Ms A Cameron-Burns, Mr D Gould, Ms R Metcalfe, M McCluskey and Mr S Carr (left 31/08/2023), Non-Executive Members, were also members of Inverclyde Integration Joint Board. |
| Renfrewshire Integration Joint Board | Charitable funding of £59,000 was provided for Renfrewshire IJB in 2023-24. | Mr J Matthews OBE, Vice-Chair, was also a Vice Chair of Renfrewshire Integration Joint Board. Ms M Kerr, Mr F Shennan (left 31/05/24), Ms J Cameron, Ms A Cameron-Burns Non-Executive Members, were also members of Renfrewshire Integration Joint Board. |
| West Dunbartonshire Integration Joint Board | Charitable funding of £31,000 was provided for West Dunbartonshire IJB in 2023-24. | Ms R Sweeney, Non-Executive Member was also a Vice Chair of West Dunbartonshire Integration Joint Board., Ms L Rousselet, Ms M Wailes, Non-Executive Members, were also members of West Dunbartonshire Integration Joint Board. |

In addition, the Charity holds investments on behalf of the Golden Jubilee National Hospital (GJNH) valued at £657,000 (2022-23: £644,000). These are included within the investments held on the balance sheet, but equally accounted for as a creditor to recognise that this amount is repayable to GJNH. The net effect in these financial statements is therefore nil. Any income generated from these investments is passed over to GJNH.